Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 5,241 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Germ Cell Neoplasms Clear all

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: mouse gp100 plasmid DNA vaccine, The Dermal PowderMed® devices, intramuscularly (IM injection); Biological · Device · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year to 120 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Glioma, Brain Neoplasm, Brain Cancer, Brain Tumor, Brain Tumor, Recurrent, Brain Neoplasm, Malignant
Interventions: Intra-arterial Cetuximab, Intra-arterial Mannitol, Hypofractionated re-irradiation; Drug · Radiation
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2036
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Renal Cell Carcinoma, Gastrointestinal Stromal Tumors, Pancreatic Neuroendocrine Tumors
Interventions: TH-302; Drug
Lead sponsor: Threshold Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Goshen, Indiana • Iowa City, Iowa

Conditions: Carcinoid
Interventions: [18F]-DOPA; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pheochromocytoma, Paraganglioma
Interventions: Not listed
Lead sponsor: Molecular Insight Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Metastatic Osteosarcoma, Metastatic Renal Cell Cancer, Sarcoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Osteosarcoma AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions: Aerosolized Aldesleukin, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years to 50 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glioblastoma Multiforme, Gliosarcoma
Interventions: DSC-MRI; Diagnostic Test
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Scottsdale, Arizona • Providence, Rhode Island • Milwaukee, Wisconsin

Conditions: Glioblastoma
Interventions: Ivonescimab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Malignant Melanoma
Interventions: Sorafenib (BAY 43-9006), ABI-007(Abraxane); Drug
Lead sponsor: Mt. Sinai Medical Center, Miami; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Los Angeles, California • Miami Beach, Florida

Conditions: Melanoma
Interventions: Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T; Genetic
Lead sponsor: Adaptimmune; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 2
States / cities: New Haven, Connecticut • St Louis, Missouri

Conditions: Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Metastatic Biliary Tract Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Biospecimen Collection, Immune Checkpoint Inhibitor; Procedure · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Solid Tumours
Interventions: Dabrafenib, Trametinib, Ipilimumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 4 more

Conditions: Melanoma
Interventions: High-performance liquid chromatography-tandem mass spectrometry assays; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 100 Years
Enrollment: 90 participants
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Newly Diagnosed Glioblastoma, Recurrent Glioblastoma
Interventions: hEGFRvIII-CD3 (BRiTE); Drug
Lead sponsor: Mustafa Khasraw, MBChB, MD, FRCP, FRACP; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Recurrent Glioblastoma
Interventions: MRI-PET, TMZ-PET; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions: 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, External Beam Radiation Therapy, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Intensity-Modulated Radiation Therapy, Iobenguane I-131, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Pharmacological Study, Questionnaire Administration, Therapeutic Conventional Surgery, Topotecan Hydrochloride, Vincristine Sulfate; Radiation · Procedure · Drug + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 30 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2025
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more

Conditions: Primary Refractory Neuroblastoma
Interventions: MAb-3F8, Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), 13-cis-Retinoic Acid; Biological
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Months to 13 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 15
States / cities: Phoenix, Arizona • San Diego, California • Washington D.C., District of Columbia + 12 more

Conditions: Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors, SMARCA4-deficient Primary CNS Malignant Tumors, Malignant Rhabdoid Tumor (MRT), Rhabdoid Tumor of the Kidney (RTK), Epithelioid Sarcoma, Chordoma
Interventions: Tazemetostat, Nivolumab, Ipilimumab; Drug
Lead sponsor: Susan Chi, MD; Other
Eligibility: 6 Months to 21 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Advanced Solid Tumors, Triple Negative Breast Cancer, Chordoma and Alveolar Soft Part Sarcoma
Interventions: FAZ053, PDR001; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Brain Neoplasms, Glioma, Medulloblastoma
Interventions: RMP-7 and carboplatin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma, Metastatic Melanoma
Interventions: CDX-301, NEOVAX, Nivolumab, Pembrolizumab; Drug · Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Head and Neck Cancer, Mucositis, Oral Complications of Radiation Therapy, Pain
Interventions: doxepin hydrochloride, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 120
States / cities: Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 77 more

Conditions: Brain and Central Nervous System Tumors, Pediatric Germ Cell Tumor, Extragonadal Germ Cell Tumor
Interventions: cisplatin, etoposide, conventional surgery, neoadjuvant therapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 3 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2005
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Melanoma, Malignant Melanoma
Interventions: T3011 + Cobimetinib; Combination Product
Lead sponsor: ImmVira Pharma Co. Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Canton, Ohio

Search by objective public record fields.

Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors

Natural History of Familial Carcinoid Tumor

Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma

Aerosolized Aldesleukin in Treating Patients With Lung Metastases

Multi-site Validation and Application of a Consensus DSC-MRI Protocol

A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma

A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant Melanoma

BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma

Bevacizumab w / Temozolomide PET & Vascular MRI For GBM

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

Cisplatin and Etoposide Prior to Radiation Therapy in Treating Patients With CNS Tumors

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma